Efficacy of Low-Intensity Extracorporeal Shock Wave Therapy on Men With Chronic Pelvic Pain Syndrome Refractory to 3-As Therapy

Shiao-Jin Guu1, Jiun-Hung Geng1,2, I-Ting Chao3, Hui-Tzu Lin3, Yung-Chin Lee1,2,4, Yung-Shun Juan1,4,5, Chia-Chhu Liu1,4, Chii-Jye Wang1,4, and Chia-Chun Tsai1,5

Abstract
Managing patients with chronic pelvic pain syndrome (CPPS) refractory to the traditional 3-As therapy (antibiotics, alpha-blockers, and anti-inflammatories) is a challenging task. Low-intensity extracorporeal shock wave therapy (LI-ESWT) was recently reported to be able to improve pain, urinary symptoms, and even sexual function by inducing neovascularization and anti-inflammation, reducing muscle tone, and influencing nerve impulses. This study evaluates whether combined treatment with LI-ESWT can restore clinical ability and quality of life (QoL) in patients refractory to 3-As therapy. This was an open-label, single-arm prospective study. Patients with CPPS without more than a 6-point decrease in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score under the maximal dosage of 3-As therapy were enrolled. LI-ESWT treatment consisted of 3,000 shock waves administered once weekly for 4 weeks. The NIH-CPSI, visual analog scale (VAS) score, International Prostate Symptom Score (IPSS), and the five-item version of the International Index of Erectile Function (IIEF-5) were used to evaluate efficacy at 1, 4, and 12 weeks after LI-ESWT. Thirty-three patients were enrolled in this study. After LI-ESWT treatment, 27 of the 33 patients (81.82%) had a successful response to LI-ESWT, with a decrease of 3.29 and 5.97 in the VAS score and total IPSS at the 3-month follow-up. Waist circumference was the only significant predictor of a successful response to LI-ESWT. LI-ESWT can serve as a salvage therapy for patients with CPPS refractory to traditional 3-As therapy. Further studies are needed to determine an adequate therapeutic protocol and important predictors in patients with different CPPS etiologies.

Keywords
shock wave therapy, chronic pelvic pain syndrome, 3-As therapy

Received July 15, 2017; revised September 6, 2017; accepted September 11, 2017

Chronic pelvic pain syndrome (CPPS), defined as non-specific, poorly localized pelvic pain without an identifiable pathology for at least 3 of the preceding 6 months, is classified as category III of prostatitis by the National Institutes of Health (NIH; Krieger, Nyberg, & Nickel, 1999). It is a common disorder in men, with the average prevalence at different ages being reported as approximately 10% (Nickel, Downey, Hunter, & Clark, 2001). Global statistics identified that the epidemiology ranges from 2.2 to 9.7%, with a mean prevalence of 8.2% (Krieger, Lee, Jeon, Cheah, & Lion, 2008). CPPS-like symptoms greatly affect urinary symptoms, quality of life (QoL), and even sexual function (Li & Kang, 2016; Walz...
et al., 2007). Although the pathophysiology of CPPS is usually multifactorial, the most common etiology is physiological disorders (Engeler et al., 2013; Magistro, Wagenlehner, Grabe, Weidner, & Stief, 2016). By covering major physiological etiologies, directed 3-As therapy (antibiotics, alpha blockers, and anti-inflammatories), rather than monotherapy, is often used as a first-line treatment for patients with CPPS because of its convenience and good efficacy (Anothaisintawee, Attia, Nickel, Thammakraisons, & Numthavaj, 2011; Thakkinstian, Attia, Anothaisintawee, & Nickel, 2012). Up to 46% of patients with CPPS do not respond sufficiently to the traditional 3-As therapy (Thakkinstian et al., 2012).

Traditional second-line treatments, including phytotherapy, hormone agents, neuromodulators, physical therapies, psychological treatment, or lifestyle modifications could serve as salvage therapies for patients with refractory CPPS (Herati & Moldwin, 2013; Magistro et al., 2016). Other invasive procedures, such as transcutaneous electrical nerve stimulation, intraprostatic injection, and even radical prostatectomy, have been discussed (Chopra, Satkunasivam, & Aron, 2016; Schneider, Tellenbach, Mordasini, Thalmann, & Kessler, 2013). Although these treatments are sometimes effective, they have many disadvantages, such as invasiveness, inconvenience, or side effects, and most patients may withdraw from them. Since 2009, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) demonstrated the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network to approach CPPS in a systemic manner. It described a new and novel description of clinical phenotyping with seven domains, including urinary, psychosocial, organ specific, infection, neurologic/systemic, tenderness, and sexual dysfunction (UPOINTS), is recommended to manage the poly-symptomatic presentation of patients with CPPS (Magistro et al., 2016; Shoshkes, Nickel, Dolinga, & Prots, 2009). After a phenotype-directed approach, arranging a safe, convenient, and noninvasive therapy that can cover the remaining domains (such as organ specific, neurologic, sexual dysfunction, and tenderness) of UPOINTS to maximize the treatment effects in patients with refractory CPPS would be reasonable.

Low-intensity extracorporeal shock wave therapy (LI-ESWT), a noninvasive therapy, has been applied recently in the treatment of CPPS (Marszalek, Berger, & Madersbacher, 2009) because it can induce neovascularization and anti-inflammation, nerve impulse interruption, reduce passive muscle tone, influence neuroplasticity of the pain memory, and is well applied in musculoskeletal disorders, peripheral neuropathy, and inflammatory diseases (Hauser & Nogrady, 2013; Mani-Babu, Morrissey, Waugh, Screeen, & Barton, 2015; Mariotto, Prati, Cavaliere, Amelio, & Marlinghuas, 2009; Schmitz, Caszser, Milz, Schieker, & Maffulli, 2015). Zimmermann et al. demonstrated that extracorporeal shock waves at a low-energy density could enhance improvement of pain, urination, erectile function, and QoL (Zimmermann, Cupanas, Miclea, & Janetschek, 2009). Although most of the published results identified that LI-ESWT can be a useful treatment for patients with CPPS, particularly those who are still responders to 3-As therapy (Marszalek et al., 2009; Pajovic, Radojevic, Dimitrovski, & Vukovic, 2016; Zimmermann et al., 2009), few studies have evaluated the role of LI-ESWT in patients with refractory CPPS who were nonresponders to 3-As therapy. The aim of the current study is to evaluate whether a combined phenotype-directed approach and LI-ESWT can improve clinical symptoms and QoL in Taiwanese patients refractory to 3-As therapy.

Materials and Methods

This was an open-label, single-arm prospective study. Patients who were unable to achieve clinical improvement after receiving full dosages of the 3-As therapy between January 2016 and December 2016 were enrolled from Kaohsiung Municipal Ta-Tung Hospital and Hsiao-Kang Hospital, in southwestern Taiwan. Eligible subjects were more than 18 years old and in a stable mental status. All patients had received at least a 6-week trial of 3-As therapy, including fluoroquinolone (500 mg once daily), alpha-blocker (recommend dose once daily), and acetaminophen/nonsteroidal anti-inflammatory drug (NSAID; recommend dose twice or three times daily). These patients did not have more than a 6-point decrease in the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) total score after taking the full course and maximal dosage of the 3-As therapy for at least 3 of the preceding 6 months (Thakkinstian et al, 2012). If unrecognized hypogonadism with serum total testosterone levels <350 ng/dL was noted during initial screening, a testosterone replacement therapy (TRT) trial of at least 3 months was performed first to restore testosterone levels to a normal range (Aversa, Francamano, & Lenzi, 2015; Wang et al., 2009). If prostate-specific antigen (PSA) levels >4 ng/mL were noted during initial screening, prostate biopsy was performed first to exclude potential malignancy. Before the LI-ESWT treatment period, all patients received phenotype-directed approach by a urologist. Subjects were excluded if they had significant coagulopathy, perineal anatomical abnormalities, neurological abnormalities, unstable psychiatric disorders, uncorrected hormone abnormalities, clinically significant medical diseases, and history of extensive pelvic surgery or irradiation. Subjects
with unstable psychosocial problems were excluded, and specialist counseling was performed simultaneously, unless their condition had improved. Only those subjects who still failed to respond to 3-As therapy after their clinical phenotypes were reevaluated and corrected were enrolled. The study protocol was approved by the Institutional Review Board of Kaohsiung Medical University Hospital. Each participant provided signed informed consent.

**Initial Screening**

All participants were assessed using a structured questionnaire to collect their demographic information and detailed medical, surgical, psychiatric, and sexual history. The well-known risk factors for CPPS, including genitourinary tract infection, pelvic organ surgery/trauma, psychological disorder, diabetes, hypertension, hyperlipidemia, cardiovascular disease, peripheral or central neuropathy, sleep disorder, hypogonadism, cigarette smoking, alcohol drinking, betel nut chewing, sexual activity, and exercise habits were completely reviewed (Gallo, 2014; Pontari & Ruggieri, 2004; Zhang, Sutcliffe, Giovannucci, Willett, & Platz, 2015). The subjects were classified as alcohol drinkers, cigarette smokers, or betel nut chewers if they had consumed any alcoholic beverage ≥1 time per week, had smoked ≥10 cigarettes per week, or had chewed ≥10 betel nuts per week for at least 6 months. Current users were those who were still using any of these substances within 1 year before the interview (Liu, Lee, Tsai, Cheng, & Wu, 2015; Zhang et al., 2015). The subjects were classified as those who had regular sexual activity or exercise habits if they had sexual activity at least two times per week or exercised 30 to 60 min per day, 2 to 3 times per week, respectively, for at least the past 6 months (Gallo, 2014; Kwak, Um, Son, & Kim, 2008). In addition to a detailed physical examination, 20-mL blood samples were drawn from all participants between 8:00 and 11:00 AM after overnight fasting >8 hr, for analyses of serum glucose, lipid panels, routine biochemical profiles, PSA, and total testosterone levels. The well-known risk factors for CPPS, including genitourinary tract infection (60.6%), the prevalence of having been diagnosed with sleep disorder (63.6%) and a history of genitourinary tract infection (60.6%). The prevalence of current smoking and regular exercise was 39.4 and

**Treatment Protocol**

All participants underwent LI-ESWT (Duolith SD1 T-TOP, Storz, Switzerland) once weekly for 4 weeks in an outpatient setting without local or systemic anesthesia. At each treatment session, LI-ESWT was applied on the perineum at six different anatomical sites (500 shocks per site with a total of 3,000 shocks) with an energy setting of 0.25 mJ/mm² at a frequency of 240 shocks/min. Because the penetration depth of LI-ESWT is adequate for covering the pelvic organs, the application site at the perineum differed for achievement of maximal treatment. During the LI-ESWT treatment period, patients added or remained on their regular medicine dosing schedules, including alpha-blockers and anti-inflammatories, in subjects with special domains. Because all patients had received full-dose antibiotics before enrolling into this study, antibiotics were not used. Dose tapering of the anti-inflammatories and alpha-blockers was allowed and dependent on the clinical condition.

**Outcome Measures of LI-ESWT**

Clinical symptoms of the participants were reassessed using NIH-CPSI score, VAS score, IIEF-5, and IPSS at 1, 4, and 12 weeks after a complete course of LI-ESWT. The main outcome measure for efficacy of LI-ESWT was the NIH-CPSI total score. Treatment success was defined as a 6-point decrease or greater in the NIH-CPSI total score, which provided a valid outcome measure for response to therapy (Litwin, 2002). During treatment, any adverse effect associated with LI-ESWT was recorded. The protocol and its application are depicted in Figure 1.

**Statistical Analysis**

Quantitative data were represented as means ± standard deviations (SD), and categorical data were represented as numbers (n) and percentages. To quantify the difference between subjects with and without response to LI-ESWT, categorized variables were compared using the chi-square test and Fisher’s exact test, whereas continuous variables were compared using the Student’s t-test. For all statistical analyses, p < .05 was considered statistically significant. All statistical analyses were performed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA).

**Results**

A total of 33 patients with a mean age of 46.55 ± 13.15 years and waist circumference of 86.12 ± 7.49 cm were enrolled. The mean history of CPPS was 43.14 months (range: 6–360 months), with 17 patients (51.5%) CPPS IIIa and 16 patients (48.5%) CPPS IIIb. Because patients could have more than one comorbidity, all comorbidities are reported in Table 1. More than half of the patients had been diagnosed with sleep disorder (63.6%) and a history of genitourinary tract infection (60.6%). The prevalence of current smoking and regular exercise was 39.4 and
American Journal of Men's Health 12(2)

45.5%, respectively. The mean serum PSA was 1.59 ± 1.57 ng/mL. Of the 33 patients, 2 (6.1%) had serum PSA levels >4 ng/mL. With regard to medical treatment with an insufficient response before LI-ESWT, our patients failed to respond to a maximal dosage of antibiotics, anti-inflammatory drugs, and alpha-blockers, in a mean trial of 3.76, 9.59, and 23.7 months, respectively (Table 1).

Changes in clinical symptoms at the 1-week, 1-month, and 3-month follow-up after 4 weeks of LI-ESWT are reported in Table 2. The mean value of the NIH-CPSI total score decreased from 28.03 ± 6.18 to 18.97 ± 8.35 and 15.06 ± 7.67, with a difference of 9.06 and 12.97 (p < .001) at the 1-month and 3-month follow-up period, respectively. Of 33 patients, 27 (81.82%) had a successful response (6-point decrease or greater in the NIH-CPSI total score) to LI-ESWT, with a decrease of 3.29 and 5.97 in VAS score and total IPSS, respectively, at the 3-month follow-up period. The mean value of the IIEF-5 also increased from 17.52 ± 4.71 to 19.42 ± 4.12 points, with a difference of 1.9 (p = .002) at the 3-month follow-up. No difference was identified in IELT after LI-ESWT (p = .177). The improvement of pain, urination, and erectile function could be noted at 1-week follow-up and persistent at the 1-month and 3-month follow-up (Figure 2). No adverse effect associated with LI-ESWT, such as hematuria, hemospermia, perineal pain, or ecchymosis, was seen in any of the patients.

Clinical characteristics and laboratory data of subjects with and without a response to LI-ESWT at the 3-month follow-up period revealed no significant difference in age, body mass index (BMI), CPPS period and category, common comorbidities, lifestyle, current cigarette smoking and alcohol drinking, or laboratory data (Table 3). However, subjects with higher waist circumference at baseline had a significantly low response rate to LI-ESWT (p = .022).
Discussion

All patients had undergone at least a 6-week trial of 3-As therapy, received adequate education by a urologist about the optimization of their 3-As use, and their clinical phenotypes of UPOINTS were reevaluated and corrected before enrolling in this study. Therefore, the current study population represented true nonresponders to 3-As therapy, which is a significant challenge to manage in clinical practice. In this study, 75.8% of patients with refractory CPPS who failed to respond to traditional 3-As therapy could achieve a clinical significant improvement after 4 weeks of LI-ESWT treatment; even more subjects (81.8%) were able to maintain the therapeutic efficacy at the 3-month follow-up. The current results are compatible with those of previous studies (Table 4). In addition, none of the patients reported any adverse effect associated with LI-ESWT.

Because multiple physiological disorders account for major etiologies in most patients with CPPS, 3-As therapy, which covers several domains of UPOINTS, has been widely accepted as a first-line treatment for CPPS (Anothaisintawee et al., 2011; Engeler et al., 2013; Magistro et al., 2016; Thakkinstian et al., 2012). However,
up to 46% of patients with CPPS are still refractory to the adequate trial and maximum dosage of 3-As therapy in clinical practice, particularly among difficult-to-treat subpopulations (e.g., patients with prolonged symptoms and multifocal pain points; Thakkinstian et al., 2012). Lifestyle modification, physiotherapy, trigger point massage, rectal massage, thermotherapy, reevaluating UPOINTS, switching to another type of 3-As medicine, and alternative medical approaches (such as phytotherapy, pentosan polysulfate, antidepressants, steroids, 5α-reductase inhibitors, anticholinergics, antispasmodics, and traditional Chinese medicine) are the common strategies adopted for nonresponders to 3-As therapy. Other invasive procedures, such as transcutaneous electrical nerve stimulation, electromagnetic treatment, acupuncture, balloon dilatation, laser coagulation, neuromodulation, intraprostatic injection, and even radical prostatectomy, were discussed (Chopra et al., 2016; El-Enen et al., 2015; Herati & Moldwin, 2013; Magistro et al., 2016; Marszalek et al., 2009; Schneider et al., 2013). However, their efficacy is usually unsatisfactory and none of these procedures has entered clinical practice on a broader scale.

LI-ESWT, a noninvasive treatment that can reduce passive muscle tone, influence neuroplasticity and, most importantly, induce neovascularization and anti-inflammatory action, has become a novel, alternative treatment for CPPS (Hausner & Nogradi, 2013; Mani-Babu et al., 2015; Mariotto et al., 2009; Schmitz et al., 2015). The hypothesis on the appropriate energy from LI-ESWT that could induce shear stress and intracellular microtrauma, and then stimulate endothelial nitric oxide synthase (eNOS) and release of vascular endothelial growth factors (VEGF) and proliferating cell nuclear antigen (PCNA), resulting in angiogenesis, has been proved in several animal studies (Wang et al., 2003; Goertz, Von der Lohe, Lauer, Khosrawipour, & Ring, 2014; Tepeköylü, Wang, Kozaryn, Albrecht-Schgoer, & Theurl, 2013). Another possible mechanism through which LI-ESWT can improve CPPS may be mediated by anti-inflammatory action. Mariotto et al. reported that LI-ESWT could induce downregulation of NF-kB and NF-kB-dependent inflammatory genes, resulting in beneficial action on tissue inflammation (Mariotto et al., 2009). LI-ESWT could also recruit endogenous mesenchymal stem cells to promote angiogenesis, tissue repair, and nerve generation in a rat model of pelvic neurovascular injuries (Li et al., 2016). Based on the gate control theory, LI-ESWT could stimulate high-frequency nerve impulses on the nociceptors, which then block the nerve impulse, by alleviating pain (Wess, 2008). The dose–effect relationship in ESWT should be of concern (Zhang, Yan, Wang, Tang, & Chai, 2014), and the optimal parameters of ESWT for CPPS are not yet determined.

Although LI-ESWT has been used in urology for treating Peyronie’s disease and erectile dysfunction (Fojecki, Tiessen, & Oster, 2017), Zimmermann et al. first reported the experience of using LI-ESWT in the treatment of CPPS in 2008 (Zimmermann, Cumpanas, Hoeltl, Janetschek, & Stenzl, 2008). In recent years, limited

### Table 2. Change of Clinical Symptoms After LI-ESWT (n = 33).

| Parameter          | Baseline | After LI-ESWT |
|--------------------|----------|---------------|
|                    | W0       | W5            | W8            | W16           | p value  |
| NIH-CPSI, Mean (± SD) | 28.03 (6.18) | 18.48 (6.97) | 18.97 (8.35) | 15.06 (7.67) | <.001    |
| Pain subscales     | 12.85 (3.17) | 7 (3.67) | 7.79 (4.72) | 5.64 (4.21) | <.001    |
| Urinary subscales  | 5.85 (2.40) | 4.55 (2.55) | 3.94 (2.37) | 3.67 (2.30) | <.001    |
| QoL subscales      | 9.33 (2.10) | 6.94 (2.59) | 7.24 (2.81) | 5.76 (2.65) | <.001    |
| CPSI decline ≥6, n (%) | NA 25 (75.80) | 25 (75.80) | 27 (81.82) | 27 (81.82) | <.001    |
| VAS, mean (± SD)   | 5.56 (1.64) | 2.79 (1.98) | 3.18 (2.40) | 2.27 (2.18) | <.001    |
| IPSS, mean (± SD)  | 14.97 (8.88) | 11.55 (7.19) | 9.79 (7.52) | 9 (6.59) | <.001    |
| Irritative score   | 6.82 (3.17) | 5.33 (2.71) | 4.55 (2.99) | 4.15 (2.86) | <.001    |
| Obstructive score  | 8.15 (6.11) | 6.21 (5.08) | 5.24 (4.94) | 4.85 (3.99) | <.001    |
| IPSS-5, mean (± SD) | 17.52 (4.71) | 19.03 (4.22) | 18.97 (4.47) | 19.42 (4.12) | <.001    |
| EHS, mean (± SD)   | 3.18 (0.92) | 3.45 (0.79) | 3.45 (0.71) | 3.48 (0.71) | <.001    |
| IELT (min), mean (± SD) | 4.39 (2.84) | 4.53 (2.87) | 3.89 (2.64) | 4.09 (2.85) | <.001    |
| Medication tapering, n (%) | NA 24 (72.70) | 28 (84.80) | 29 (87.90) | 29 (87.90) | <.001    |
| Current painkiller use, n (%) | NA 23 (69.70) | 18 (54.50) | 12 (36.40) | 12 (36.40) | <.001    |

Note. EHS = erection hardness score; IELT = intravaginal ejaculation latency time; IPSS = International Prostate Symptom Score; LI-ESWT = low-intensity extracorporeal shockwave therapy; NIH-CPSI = National Institutes of Health Chronic Prostatitis Symptom Index, QoL = quality of life; SD = standard deviation; VAS = visual analog scale; W = week.
studies on LI-ESWT have reported positive results in the improvement of CPPS. The current study reviewed studies since 2008 in Table 4 (Al Edwan, Muheilan, & Atta, 2017; Moayednia, Haghdani, Khoosrawi, Yousefi, & Vahdatpour, 2014; Pajovic et al., 2016; Vahdatpour, Alizadeh, Moayednia, Emadi, & Khorami, 2013; Zeng, Liang, & Ye, 2012; Zimmermann et al., 2008; Zimmermann et al., 2009). Most of them had limited patient numbers or were not randomized controlled trials. The long-term effect of LI-ESWT is still equivocal (Al Edwan et al., 2017; Moayednia et al., 2014), and only one study prior to the current study had evaluated the role of LI-ESWT in the treatment of patients with CPPS who were non-responders to traditional 3-As therapy (Al Edwan et al., 2017). Because different generators and protocols of LI-ESWT were used in previous studies, the current results can only be compared with the other four studies that used the same device. Further studies are still needed to define an adequate therapeutic protocol, including location of the applied probe, energy density, and number of pulses and sessions, and to determine important predictors of successful response to LI-ESWT in patients with CPPS.

In the current study, most patients had concomitant alpha-blocker and anti-inflammatory drug use during and after LI-ESWT. After 12 weeks of LI-ESWT treatment, up to 72.7% of patients could taper 3-As medication and only 36.4% of patients still needed painkillers. The

**Figure 2.** The improvement of pain, urination, and erectile function during 1-week, 1-month, and 3-month follow-up.
Table 3. Comparison of Clinical Characteristics and Laboratory Data Between Subjects With and Without Response to LI-ESWT.

| Parameter                                             | Subjects without response (N = 6) | Subjects with response (N = 27) | p value |
|-------------------------------------------------------|-----------------------------------|---------------------------------|---------|
| Age (years), mean (±SD)                               | 42.67 (16.12)                     | 47.41 (12.58)                   | .433    |
| BMI (kg/m²), mean (±SD)                               | 25.85 (3.97)                      | 24.00 (2.44)                    | .147    |
| Waistline (cm), mean (±SD)                            | 92.33 (10.30)                     | 84.74 (6.13)                    | .022    |
| CPSS period (months), mean (±SD)                      | 31.67 (26.65)                     | 45.69 (68.43)                   | .629    |
| CPSS category, n (%)                                  |                                   |                                 |         |
| CPPS IIIa                                             | 4 (66.70)                         | 13 (48.10)                      | .656    |
| CPPS IIIb                                             | 2 (33.30)                         | 14 (51.90)                      |         |
| Comorbidities, n (%)                                  |                                   |                                 |         |
| Genitourinary tract infection                         | 4 (66.70)                         | 16 (59.30)                      | >.999   |
| Pelvic organ surgery or trauma                         | 2 (33.30)                         | 4 (14.80)                       | .295    |
| Psychological disorder                                | 1 (16.70)                         | 3 (11.10)                       | >.999   |
| Diabetes mellitus                                     | 1 (16.70)                         | 1 (3.70)                        | .335    |
| Hypertension                                          | 1 (16.70)                         | 5 (18.50)                       | >.999   |
| Hyperlipidemia                                        | 2 (33.30)                         | 7 (25.90)                       | >.999   |
| Cardiovascular disease                                | 1 (16.70)                         | 1 (3.70)                        | .335    |
| Peripheral or central neuropathy                      | 0 (0.00)                          | 4 (14.80)                       | NA      |
| Hypogonadism                                          | 2 (33.30)                         | 4 (14.80)                       | .295    |
| Current smoking                                       | 2 (33.30)                         | 11 (40.70)                      | >.999   |
| Current alcohol drinking                              | 1 (16.70)                         | 11 (40.70)                      | .379    |
| Current betel nut chewing                             | 1 (16.70)                         | 2 (7.40)                        | .464    |
| Sleep disorder                                        | 5 (83.30)                         | 16 (59.30)                      | .379    |
| No regular exercise                                   | 3 (50.00)                         | 15 (55.60)                      | >.999   |
| No regular sex                                        | 2 (33.30)                         | 7 (25.90)                       | >.999   |
| Number of comorbidities, mean (±SD)                   | 5.33 (2.94)                       | 4.04 (2.17)                     | .224    |
| History of medicine (months), mean (±SD)              |                                   |                                 |         |
| Antibiotics                                           | 2.67 (1.72)                       | 4 (3.59)                        | .387    |
| Anti-inflammatory                                     | 8.33 (4.92)                       | 9.87 (9.77)                     | .173    |
| Alpha-blocker                                         | 18.83 (23.60)                     | 24.78 (47.72)                   | .77     |
| Laboratory data, mean (±SD)                           |                                   |                                 |         |
| Total testosterone (ng/dL)                            | 493.4 (173.99)                    | 527.15 (172.39)                 | .668    |
| Prostate-specific antigen (ng/mL)                     | 2.53 (2.57)                       | 1.38 (1.24)                     | .106    |
| Initial clinical severity, mean (±SD)                 |                                   |                                 |         |
| NIH-CPSI                                               |                                   |                                 |         |
| Total score                                           | 24.33 (7.45)                      | 28.85 (5.70)                    | .106    |
| Pain subscales                                        | 11.83 (4.07)                      | 13.07 (2.99)                    | .395    |
| Urinary subscales                                     | 4.33 (2.81)                       | 6.19 (2.22)                     | .087    |
| QoL subscales                                         | 8.17 (3.43)                       | 9.59 (1.67)                     | .135    |
| VAS                                                    | 5.00 (2.68)                       | 5.70 (1.35)                     | .350    |
| IPSS                                                   |                                   |                                 |         |
| Total score                                           | 11.67 (9.03)                      | 15.70 (8.74)                    | .316    |
| Irritative score                                      | 6.00 (6.51)                       | 8.63 (6.04)                     | .348    |
| Obstructive score                                     | 5.67 (2.88)                       | 7.07 (3.22)                     | .333    |
| IIEF-5                                                 | 18.33 (4.13)                      | 17.33 (4.88)                    | .645    |
| EHS                                                    | 3.17 (0.98)                       | 3.19 (0.92)                     | .965    |

Note. BMI = body mass index; CPPS = chronic pelvic pain syndrome; EHS = erection hardness score; IIEF-5: five-item version of the International Index of Erectile Function; IPSS = International Prostate Symptom Score; LI-ESWT = low-intensity extracorporeal shockwave therapy; NIH-CPSI = National Institutes of Health Chronic Prostatitis Symptom Index, QoL = quality of life; SD = standard deviation; VAS = visual analog scale.
| Authors                  | Study design | Generator | Patient number | Follow-up (weeks after ESWT) | Energy density (mJ/mm²) | No. of pulses each treatment | Frequency (shocks/min) | No. of treatments each week | Treatment courses (weeks) | Neoadjuvant therapy before LI-ESWT | Concomitant therapy during LI-ESWT | Adjuvant therapy after LI-ESWT | NIH-CPSI | VAS | IPSS |
|-------------------------|--------------|-----------|----------------|------------------------------|-------------------------|----------------------------|------------------------|---------------------------|-----------------------------|-------------------------------|---------------------------------|-------------------------------|-----------|-----|------|
| Zimmermann et al., 2008| Cohort study | Minilith SL1 | 14             | 1, 4, 12                    | 0.11                     | 2000                       | 180                    | 3                         | 2                           | NA                             | No                              | No                              | −2.7(1 wk) | −3.1(1 wk) | NA   |
| Zimmermann et al., 2008| Cohort study | Duolith SD1 | 20             | 1, 4, 12                    | 0.25                     | 3000                       | 180                    | 1                         | 4                           | NA                             | No                              | No                              | −8.6(1 wk) | −8.9(4 wk) | −5.1(1 wk) |
| Zimmermann et al., 2009 | RCT          | Duolith SD1 | 30             | 1, 4, 12                    | 0.25                     | 3000                       | 180                    | 1                         | 4                           | NA                             | No                              | No                              | −16.7(1 wk) | −16.7(4 wk) | −16.7(12 wk) |
| Zeng et al, 2012        | RCT          | HB-ESWT-01 | 8              | 4.12                        | 0.06–MTD                 | 2000                       | 120                    | 5                         | 2                           | Yes                            | No                              | No                              | CPSI ↓ ≥6: | NA         | NA   |
| Vahdatpour et al, 2013  | RCT          | Duolith SD1 | 40             | 1, 2, 3, 12                 | 0.25–0.4                 | 3000                       | 180                    | 1                         | 4                           | NA                             | No                              | No                              | −5.1(1 wk) | −10.2(3 wk) | −7.1(12 wk) |
| Moayednia et al, 2014   | RCT          | Duolith SD1 | 19             | 16, 20, 24                  | 0.25                     | 3000                       | 180                    | 1                         | 4                           | NA                             | NA                              | NA                              | −4.47(16 wk) | −9.3(12 wk) | −0.71(16 wk) |
| Pajovic et al, 2016 RCT | KM-2000 S    | 30         | 12, 24         | 0.25                        | 3000                     | 180                       | 12                     | No                        | Yes                         | NA                             | −1.9(12 wk)                     | −3.2(24 wk)                   | −2.66(16 wk) | −1.24(20 wk) | −0.39(20 wk) |
| Al Edwan et al, 2017    | Cohort study | E-S.W.T Roland, pagani, Italy | 41 | 2, 24, 48 | 0.25 | 2500 | 180 | 12 | No | Yes | NA | −9.2(2 wk) | −4.1(2 wk) | −5.9(2 wk) | −2.9(12 wk) |
| Our study               | Cohort study | Duolith SD1 | 33             | 1, 4, 12                    | 0.25                     | 3000                       | 240                    | 1                         | 4                           | Yes                            | Yes                             | Yes                             | −9.06(4 wk) | −2.8(4 wk) | −5.2(12 wk) |

Note: IPSS = International Prostate Symptom Score; LI-ESWT = low-intensity extracorporeal shock wave therapy; MTD = maximum tolerated dose; NA = not available; NIH-CPSI = National Institutes of Health-Chronic Prostatitis Symptom Index; RCT = randomized controlled trial; VAS = Visual Analogue Scale.

*In NIH-CPSI pain domain. †In NIH-CPUI urinary domain.
efficacy was maintained even better at the 3-month follow-up. The good efficacy of LI-ESWT in refractory CPPS may be because the therapy can cover the remaining domains of UPOINTS (such as organ specific, neurologic/systemic, tenderness, and even sexual dysfunction) to maximize the treatment effects. 3-As therapy only covers parts of UPOINTS, such as the domains of urinary and organ-specific function, infection, whereas LI-ESWT can play a part in other domains, thereby complementing the positive effect from a different perspective. In addition, no statistically significant difference in age, BMI, CPPS period and category, comorbidities, and personal habits was reported in the current study when responders were compared with nonresponders to LI-ESWT. Waist circumference was identified to be the only significant predictor in patients with CPPS who fail to respond to traditional 3-As therapy. At the 3-month follow-up had a larger waist circumference ($p = .022$). In an in vitro study, the energy of LI-ESWT was reported to slowly decay or attenuate in fat tissue because it could not accumulate adequate energy in the target (Liang, Zheng, Yan, Wan, & Wen, 2010). In contrast, Rogowski et al. reported that waist circumference appears to exert the most influence upon the presence and intensity of the inflammatory markers and micro-inflammatory response (Rogowski et al., 2010). Thus, larger waist circumference, as the primary contributor of the inflammatory state and energy decay, might be a negative predictive factor for LI-ESWT in patients with CPPS.

The current study has several limitations. First, it was a single-arm prospective study, which lacks control or comparison to other types of therapy. Second, the patient number was limited; hence, comparison of the efficacy of LI-ESWT for different etiologies of CPPS is difficult. Third, the follow-up period was only 3 months; hence, the long-term efficacy of LI-ESWT could not be evaluated.

Conclusions

LI-ESWT can serve as a salvage therapy in patients with CPPS who fail to respond to traditional 3-As therapy. At the 3-month follow-up, 81.8% of refractory patients with CPPS achieved a clinically significant improvement. Waist circumference was identified to be the only significant predictor of successful response to LI-ESWT. Further large and long-term studies are needed to compare the efficacy of different generators of LI-ESWT and to determine an adequate therapeutic protocol and important predictors in patients with different CPPS etiologies.

Declarations of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by grants from Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan (KMTTH104-3R23). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

Al Edwan, G. M., Muheilan, M. M., & Atta, O. N. (2017). Long term efficacy of extracorporeal shock wave therapy [ESWT] for treatment of refractory chronic abacterial prostatitis. *Annals of Medicine and Surgery*, 14, 12–17. doi:10.1016/j.amsu.2016.12.051

Anothaisintawee, T., Atitaj, J., Nickel, J. C., Thammakraisorn, S., Numthavaj, P., McEvoy, M., & Thaknkistian, A. (2011). Management of chronic prostatitis/chronic pelvic pain syndrome: A systematic review and network meta-analysis. *Journal of the American Medical Association*, 305(1), 78–86. doi:10.1001/jama.2010.1913

Aversa, A., Francomano, D., & Lenzi, A. (2015). Does testosterone supplementation increase PDE5-inhibitor responses in difficult-to-treat erectile dysfunction patients? *Expert Opinion on Pharmacotherapy*, 16(5), 625–628. doi:10.1517/14656566.2015.1011124

Chopra, S., Satkunasivam, R., & Aron, M. (2016). Feasibility of robotic radical prostatectomy for medication refractory chronic prostatitis/chronic pelvic pain syndrome: Initial results. *Indian Journal of Urology*, 32(3), 238–241. doi:10.4103/0970-1591.185105

Clemens, J. Q., Mullins, C., Kusek, J. W., Kirkali, Z., Mayer, E. A., Rodriguez, L. V., . . . MAPR Research Network Study Group. (2014). The MAPR research network: A novel study of urologic chronic pelvic pain syndromes. *BMC Urology*, 14, 57. doi: 10.1186/1471-2490-14-57.

El-Enen, M. A., Abou-Farha, M., El-Abd, A., El-Tatawy, H., Tawfik, A., El-Abd, S., . . . El-Sharaby, M. (2015). Intraprostatic injection of botulinum toxin-A in patients with refractory chronic pelvic pain syndrome: The transurethral vs. transrectal approach. *Arab Journal of Urology*, 13(2), 94–99. doi:10.1016/j.aju.2015.01.001

Engeler, D. S., Baranowski, A. P., Dinis-Oliveira, P., Elneil, S., Hughes, J., Messelink, E. J., . . . European Association of Urology. (2013). The 2013 EAU guidelines on chronic pelvic pain: Is management of chronic pelvic pain a habit, a philosophy, or a science? 10 years of development. *European Urology*, 64(3), 431–439. doi:10.1016/j.eururo.2013.04.035

Fojecki, G. L., Tiessen, S., & Osther, P. J. (2017). Extracorporeal shock wave therapy (ESWT) in urology: A systematic review of outcome in Peyronie’s disease, erectile dysfunction and chronic pelvic pain. *World Journal of Urology*, 35(1), 1–9. doi:10.1007/s00345-016-1834-2

Gallo, L. (2014). Effectiveness of diet, sexual habits and lifestyle modifications on treatment of chronic pelvic pain syndrome. *Prostate Cancer and Prostatic Disease*, 17(3), 238–245. doi:10.1038/pcan.2014.18
Goertz, O., von der Lohe, L., Lauer, H., Khosrawipour, T., Ring, A., Daigeler, A., Lehnhardt, M., & Kolbenschlag, J. (2014). Repetitive extracorporeal shock wave applications are superior in inducing angiogenesis after full thickness burn compared to single application. *Burns*, 40(7), 1365–1374.

Hausner, T., & Nogradi, A. (2013). The use of shock waves in peripheral nerve regeneration: New perspectives? *International Review of Neurobiology*, 109, 85–98. doi:10.1016/b978-0-12-420045-6.00003-1

Herati, A. S., & Moldwin, R. M. (2013). Alternative therapies in the management of chronic prostatitis/chronic pelvic pain syndrome. *World Journal of Urology*, 31(4), 761–766. doi:10.1007/s00345-013-1097-0

Krieger, J. N., Lee, S. W., Jeon, J., Cheah, P. Y., Liong, M. L., & Riley, D. E. (2008). Epidemiology of prostatitis. *Internal Journal of Antimicrobial Agents*, 31 Suppl 1, S85–S90. doi:10.1016/j.ijantimicag.2007.08.028

Krieger, J. N., Nyberg, L., Jr., & Nickel, J. C. (1999). NIH consensus definition and classification of prostatitis. *Journal of the American Medical Association*, 282(3), 236–237.

Kwak, Y. S., Um, S. Y., Son, T. G., & Kim, D. J. (2008). Effect of regular exercise on senile dementia patients. *Internal Journal of Sports Medicine*, 29(6), 471–474. doi:10.1055/s-2007-964853

Li, H., Matheu, M. P., Sun, F., Wang, L., Sanford, M. T., Ning, H., ... Lue, T. F. (2016). Low-energy shock wave therapy ameliorates erectile dysfunction in a pelvic neurovascular injuries rat model. *Journal of Sexual Medicine*, 13(1), 22–32. doi:10.1016/j.jsxm.2015.11.008

Li, H. J., & Kang, D. Y. (2016). Prevalence of sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome: A meta-analysis. *World Journal of Urology*, 34(7), 1009–1017. doi:10.1007/s00345-015-1720-3

Li, Guo, Shao, Z., Zheng, K.-F., Yan, J.-J., Wan, R.-R., & Wen, C.-Y. (2010). Animal study on lysing adipose tissues by shock waves. *Journal of Medical and Biological Engineering*, 30(3), 145–151.

Litwin, M. S. (2002). A review of the development and validation of the National Institutes of Health Chronic Prostatitis Symptom Index. *Urology*, 60(6 Suppl), 14–18; discussion 18–19.

Liu, C. C., Lee, Y. C., Tsai, V. F., Cheng, K. H., Wu, W. J., Bao, B. Y., ... Huang, S. P. (2015). The interaction of serum testosterone levels and androgen receptor CAG repeat polymorphism on the risk of erectile dysfunction in aging Taiwanese men. *Andrology*, 3(5), 902–908. doi:10.1111/andr.12068

Magistro, G., Wagenlehner, F. M., Grabe, M., Weidner, W., Stief, C. G., & Nickel, J. C. (2016). Contemporary management of chronic prostatitis/chronic pelvic pain syndrome. *European Urology*, 69(2), 286–297. doi:10.1016/j.euro.2015.08.061

Mani-Babu, S., Morrissey, D., Waugh, C., Screen, H., & Barton, C. (2015). The effectiveness of extracorporeal shock wave therapy in lower limb tendinopathy: A systematic review. *American Journal of Sports Medicine*, 43(3), 752–761. doi:10.1177/0363546514531911

Mariotto, S., de Prati, A. C., Cavaleri, E., Amelio, E., Marlinghaus, E., & Suzuki, H. (2009). Extracorporeal shock wave therapy in inflammatory diseases: Molecular mechanism that triggers anti-inflammatory action. *Current Medical Chemistry*, 16(19), 2366–2372.

Marszalek, M., Berger, I., & Madersbacher, S. (2009). Low-energy extracorporeal shock wave therapy for chronic pelvic pain syndrome: Finally, the magic bullet? *European Urology*, 56(3), 425–426. doi:10.1016/j.eururo.2009.03.075

Moayednia, A., Haghdani, S., Khosravi, S., Yousefi, E., & Vahdatpour, B. (2014). Long-term effect of extracorporeal shock wave therapy on the treatment of chronic pelvic pain syndrome due to non-bacterial prostatitis. *Journal of Research in Medical Science*, 19(4), 293–296.

Nickel, J. C., Downey, J., Hunter, D., & Clark, J. (2001). Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. *Journal of Urology*, 165(3), 842–845.

Pajovic, B., Radojevic, N., Dimitrovski, A., & Vukovic, M. (2016). Comparison of the efficiency of combined extracorporeal shock-wave therapy and triple therapy versus triple therapy itself in Category III B chronic pelvic pain syndrome (CPPS). *Aging Male*, 19(3), 202–207. doi:10.1080/13685538.2016.1197899

Pontari, M. A., & Ruggieri, M. R. (2004). Mechanisms in prostatitis/chronic pelvic pain syndrome. *The Journal of Urology*, 172(3), 839–845. doi:10.1097/01.ju.0000136002.76898.04

Rogowski, O., Shapira, I., Bassat, O. K., Chundadze, T., Finn, T., Berliner, S., & Steinvil, A. (2010). Waist circumference as the predominant contributor to the micro-inflammatory response in the metabolic syndrome: A cross sectional study. *Journal of Inflammation (Lond)*, 7, 35. doi:10.1186/1476-9255-7-35

Schmitz, C., Csasar, N. B., Milz, S., Schieker, M., Maffulli, N., Rompe, J. D., & Furia, J. P. (2015). Efficacy and safety of extracorporeal shock wave therapy for orthopedic conditions: A systematic review on studies listed in the PEDro database. *British Medical Bulletin*, 116, 115–138. doi:10.1093/bmbld/ldv047

Schneider, M. P., Tellenbach, M., Mordasini, L., Thalmann, G. N., & Kessler, T. M. (2013). Refractory chronic pelvic pain syndrome in men: Can transcutaneous electrical nerve stimulation help? *BJU International*, 112(2), E159–E163. doi:10.1111/bju.12005

Shoskes, D. A., Nickel, J. C., Dolinga, R., & Prots, D. (2009). Clinical phenotyping of patients with chronic prostatitis/chronic pelvic pain syndrome and correlation with symptom severity. *Urology*, 73(3), 538–542; discussion 542–543. doi:10.1016/j.urology.2008.09.074

Tepeköylü, C., Wang, F. S., Kuzaryn, R., Albrecht-Schgoer, K., Theurl, M., Schaden, W., Ke, H. J., et al. (2013). Shock wave treatment induces angiogenesis and mobilizes endogenous CD31/CD34-positive endothelial cells in a hindlimb ischemia model: Implications for angiogenesis and vasculogenesis. *Journal of Thoracic and Cardiovascular Surgery*, 146(4), 971–978.
Thakkinstian, A., Attia, J., Anothaisintawee, T., & Nickel, J. C. (2012). alpha-blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome. *BJU International, 110*(7), 1014–1022. doi:10.1111/j.1464-410X.2012.11088.x

Vahdatpour, B., Alizadeh, F., Moayednia, A., Emadi, M., Khorami, M. H., & Haghdani, S. (2013). Efficacy of extracorporeal shock wave therapy for the treatment of chronic pelvic pain syndrome: A randomized, controlled trial. *International Scholarly Research Notice Urology, 2013*, 972601. doi:10.1155/2013/972601

Walz, J., Perrotte, P., Hutterer, G., Suardi, N., Jeldres, C., Benard, F., . . . Karakiewicz, I. P. (2007). Impact of chronic prostatitis-like symptoms on the quality of life in a large group of men. *BJU International, 100*(6), 1307–1311. doi:10.1111/j.1464-410X.2007.07250.x

Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., & Gooren, L. J., . . . American Society of Andrology (ASA). (2009). Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. *European Urology, 55*(1), 121–130. doi:S0302-2838(08)00972-X [pii]10.1016/j.eururo.2008.08.033 [doi]

Wang, C. J., Wang, F. S., Yang, K. D., Weng, L. H., Hsu, C. C., Huang, C. S., & Yang, L. C. (2003). Shock wave therapy induces neovascularization at the tendon-bone junction. A study in rabbits. *Journal of Orthopaedic Research, 21*(6), 984–989. doi:10.1016/s0736-0266(03)00104-9

Wess, O. J. (2008). A neural model for chronic pain and pain relief by extracorporeal shock wave treatment. *Urological Research, 36*(6), 327–334. doi:10.1007/s00240-008-0156-2

Zeng, X. Y., Liang, C., & Ye, Z. Q. (2012). Extracorporeal shock wave treatment for non-inflammatory chronic pelvic pain syndrome: A prospective, randomized and sham-controlled study. *Chinese Medical Journal (Engl), 125*(1), 114–118.

Zhang, R., Sutcliffe, S., Giovannucci, E., Willett, W. C., Platz, E. A., Rosner, B. A., et al. (2015). Lifestyle and risk of chronic prostatitis/chronic pelvic pain syndrome in a cohort of United States male health professionals. *Journal of Urology, 194*(5), 1295–1300. doi:10.1016/j.juro.2015.05.100

Zhang, X., Yan, X., Wang, C., Tang, T., & Chai, Y. (2014). The dose-effect relationship in extracorporeal shock wave therapy: The optimal parameter for extracorporeal shock wave therapy. *Journal of Surgical Research, 186*(1), 484–492. doi:10.1016/j.jss.2013.08.013

Zimmermann, R., Cumpanas, A., Hoeltl, L., Janetschek, G., Stenzl, A., & Miclea, F. (2008). Extracorporeal shock-wave therapy for treating chronic pelvic pain syndrome: A feasibility study and the first clinical results. *BJU International, 102*(8), 976–980. doi:10.1111/j.1464-410X.2008.07742.x

Zimmermann, R., Cumpanas, A., Miclea, F., & Janetschek, G. (2009). Extracorporeal shock wave therapy for the treatment of chronic pelvic pain syndrome in males: A randomised, double-blind, placebo-controlled study. *European Urology, 56*(3), 418–424. doi:10.1016/j.eururo.2009.03.043